Med. praxi. 2011;8(10):419-423

Properly selected = optimal treatment of hypertension compensation in everyday practice

MUDr.Michal Vrablík, Ph.D., MUDr.Martina Prusíková, MUDr.Eva Motyková
Centrum preventivní kardiologie, 3. interní klinika 1. LF UK a VFN, Praha

Arterial hypertension continues to rank among the most important health issues of today. Thanks to better understanding and improved

therapeutic and diagnostic options the standards of care in hypertension have improved markedly. After the publication of the

most recent results of clinical trials, target values of blood pressure have moved to the 130–140/80–90 mmHg range suitable for most

circumstances of everyday common practice. The same trials provided guidance on the best management of hypertension. Therefore,

most commonly used antihypertensive treatment is based on a blocker of the rennin-angiotensin-aldosterone system, and, if needed,

supplemented by calcium channel blocker. Combination antihypertensive treatment using fixed dose combinations does not have to

be accompanied by worsened compliance. The opposite can be true- combination of more drugs from different classes can reduce the

number of side effects and, thus, result in better and longer adherence of the patients.

Keywords: arterial hypertension, antihypertensives, combinations, cardiovascular risk

Published: October 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vrablík M, Prusíková M, Motyková E. Properly selected = optimal treatment of hypertension compensation in everyday practice. Med. praxi. 2011;8(10):419-423.
Download citation

References

  1. Cífková R, Škodová Z. Longitudinální trendy hlavních rizikových faktorů kardiovaskulárních onemocnění v české populaci. Čas Lék Čes 2004; 143(4): 219-226.
  2. Zdravotnická ročenka České republiky 2009. Ústav zdravotnických informací, www.uzis.cz.
  3. Chen G, McAlistar FA, Walker RL, et al. Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension 2011; 57: 1-7. Go to original source... Go to PubMed...
  4. Fait T, Vrablík M, Češka R. Preventivní medicína, Maxdorf, Praha 2008: 551.
  5. Williams B. Hypertension and the, ,J-curve". JACC 2009; 54(20): 1834-1835. Go to original source... Go to PubMed...
  6. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force dokument. J Hypertens. 2009 Oct 15. Go to original source... Go to PubMed...
  7. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122(3): 290-300. Go to original source... Go to PubMed...
  8. Widimský J jr, Cífková R, Špinar J, Filipovský J, Grundmann M, Horký K, et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007. Doporučení České společnosti pro hypertenzi. Vnitr Lek 2008; 54(1): 101-118. Go to PubMed...
  9. Osterloh I. The safety of amlodipine. Am Heart J 1989; 118: 1114-1120. Go to original source... Go to PubMed...
  10. Dahlöf B, Sever PS, Poulter NR, et al. For the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895-906. Go to original source... Go to PubMed...
  11. Sever P, Dahlof B, Poulter N, et al. Potential synergy between lipid-lowering and blood-pressure lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982-2988. Go to original source... Go to PubMed...
  12. Sever PS. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the AngloScandinavian Cardiac Outcomes Trial (ASCOT)? Am J Med 2005; 118(Suppl. 12A): 3S-9S. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.